Mundipharma inks biosimilars deal with Egis Pharma

Mundipharma has entered into an exclusive distribution agreement with Egis Pharmaceuticals for Pelmeg, a pegfilgrastim biosimilar treatment. The agreement covers Hungary, Romania, Latvia and Lithuania, where Mundipharma does not have a direct commercial presence.

Pelmeg is a pegfilgrastim biosimilar to Amgen’s (Nasdaq: AMGN) Neulasta that is delivered subcutaneously to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes).Pelmeg was approved in the European Union in November 2018.

Egis Pharmaceuticals is one of the leading branded generic companies in the CEE and CIS regions, belonging to the French independent Servier group, with a strong presence in the biosimilars market. Egis launched its first biosimilar monoclonal antibody medicine in 2013 and, since then, has launched three biosimilars for the treatment of autoimmune conditions, oncology and oncohematology.